Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy

Journal of Family Practice

Volumn 42, Issue 6, 1996, Pages 577-586

  Rembold, Christopher M ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Atherosclerosis; cholestyramine; coronary artery disease; dietary therapy; HMG CoA reductase inhibitors; meta analysis; niacin

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; DIHYDROPYRIDINE DERIVATIVE; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIDOCAINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DIET THERAPY; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIMARY MEDICAL CARE; SINGLE BLIND PROCEDURE;

ANTILIPEMIC AGENTS; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MYOCARDIAL INFARCTION; NIACIN; RISK FACTORS; TREATMENT OUTCOME;

EID: 0029996601     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. The Framingham Study. The epidemiology of atherosclerotic disease. Cambridge, Mass: Harvard University Press, 1980.
2. Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40:1069-118.
3. Dorr AE, Gundersen K, Schneider R, Spencer TW, Martin WB. Colestipol hydroehloride in hypercholesterolemic patients - effect on serum cholesterol and mortality. J Chron Dis 1978; 31:5-14.
4. Lipid Research Clinic Program. The lipid research clinic coronary primary prevention trial results. JAMA 1984; 251:351-64.
5. Holme I, Hjermann I, Helgeland A, Leren P. The Oslo study: diet and anti-smoking advice. Prev Med 1985; 14:279-92.
6. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-45.
7. Pravastatin Multination Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter(200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993; 72:1031-7.
8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-7.
9. Research Committee, Low-fat diet in myocardial infarction. Lancet 1965; 2:501-4.
10. Research Committee. Controlled trial of soya-bean oil in myocardial infarction. Lancet 1968; 2:693-700.
11. Dayton S, Pearce ML, Hashimoto S, Dixon WJ, Tomiyasu U. A controlled clinical trial of a diet high in unsaturated Fat in preventing complications of atherosclerosis. Circulation 1969;40(suppl II):II-1-II-63.
12. Lehen P. The Oslo diet-heart study. Circulation 1970; 42:935-42.
13. Research Committee. Trial of clofibrate in the treatment of ischaemic heart disease (Newcastle). BMJ 1971; 4:767-74.
14. Research Committee. Ischaemic heart disease: a secondary prevention trial using clofibrate (Edinburgh). BMJ 1971; 4:775-84.
15. Coronary Drug Project Research Croup. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231:360-81.
16. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223:405-18.
17. Buchwald H, POSCH (Program on the Surgical Control of the Hyperlipidemias) group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesrerolemia. N Engl J Med 1990; 323:946-55.
18. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J, Kaplan C, Zhao X, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289-98.
19. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. JAMA 1990; 264:3013-7.
20. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, et al. Can lifestyle changes reverse coronary heart disease? Lancet 1990; 336:129-33.
21. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264:3007-12.
22. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, Mann JI, Swan AV. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas Atherosclerosis Regression Study (STARS). Lancet 1992; 339:563-9.
23. Singh RB, Rastogi SS, Verma R, Laxmi B, Singh R, Ghosh S, Niaz MA. Randomized controlled trial of cardioprotective effect of diet in patients with recent acute myocardial infartion: results of one year follow up. BMJ 1992; 304:1015-9.
24. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lesperance J, CCAIT (Canadian Coronary Atherosclerosis Intervention Trial) study group. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography (CCAIT). Circulation 1994; 89:959-68.
25. MAAS (Multicenter Anti-Atheroma Study) Investigators. Effects of simvastatin on coronary atheroma: the multicenter anti-atheroma study. Lancet 1994; 344:633-8.
26. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PM, HARP (Harvard Atherosclerosis Reversibility Trial) group. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentration in normocholesterolemic patients. Lancet 1994; 344:1182-6.
27. Haskell WL, Alderman EL, Fair JM, Maron DJ, Sackey SF, Superko HR, Williams PT, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. Circulation 1994; 89:975-90.
28. Pitt B, Furherg C, McGovern M. Reduction in cardiovascular events during treatment with pravastatin: pooled analysis from coronary and carotid atherosclerosis intervention trials [abstract]. Eur Heart J 1995; 15:S487.
29. Scandinavian Simvastatin Survival Study group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9.
30. Furberg CD, Adams HP, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Letkowitz PS, Probstfield J, Riley WA, Young B, ACAPS (Asymptomatic Carotid Artery Progression Study) research group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90: 1679-87.
31. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in sypmtomatic men with with normal to moderately elevated serum cholesterol levels (Regression Growth Evaluation Statin Study |REGRESS|). Circulation 1995; 91:2528-40.
32. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, Stone NJ, et al. Effects of therapy with cholestyramine on progression of coronary atherosclerosis: results of NHLBI type II coronary intervention study. Circulation 1984; 69:313-24.
33. Schuler G, Hambrecht R, Schlierf G, Niebauer J, Hauer K, Neumann J, Hoberg E., et al. Regular physical exercise and low-fat diet - effects of progression of coronary artery disease. Circulation 1992; 86:1-11.
34. Blankenhorn DH, Azen SP, Kramsch SM, Mack WJ, Cashin-Hemphill L, Hodis HN, MARS Research Group. Coronary angiographic changes with lovastatin therapy (MARS). Ann Intern Med 1993; 119:969-76.
35. Lau J, Antman EM, Jiminez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapuetic trials for myocardial infarction. N Engl J Med 1992; 327:248-54.
36. Superko HR, Krauss RM. Coronary artery disease regression -convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994; 90:1056-69.
37. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308:367-73.
38. Truswell AS. Reveiw of dietary intervention studies: effect on cor onary events and on total mortality. Aust N Z J Med 1994; 24: 98-106.
39. Howes LG, Simons LA. Efficacy of drug intervention for lipids in the prevention of coronary artery disease. Aust N Z J Med 1994; 24:107-12.
40. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit - a new look at old data. Circulation 1995; 91:2274-82.
41. Medical Research Council (MRC) Working Party. Medical Research Council trial in the treatment of hypertension in older adults: principal results. BMJ 1992; 304:405-12.
42. Woodhill JM, Palmer AJ, Leelarthaepin B, McGlilchrist C, Blacket RB Low fat, low cholesterol diet in secondary prevention of coronary heart disease. Adv Exp Med Biol 1978; 109:317-30.
43. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweet nam PM, Ellwood PC, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial. Lancet 1989; 2:757-61.
44. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial - risk factor changes and mortality results. JAMA 1982; 248:1465-77.
45. Wilhelmsen L, Berglund G, Elmfeldt D, Tibblin G, Wedel H, Pennert K, Vedin A, et al. The Multifactor Primary Prevention Trial in Goteborg, Sweden. Eur Heart J 1986;7:279-88.
46. Arinitage P, Berry G. Statistical methods in medical research. Oxford, England: Blackwell Scientific Publications, 1994.
47. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. N Engl J Med 1987; 316:450-5.